Compugen Ltd.

From WikiMD's Wellness Encyclopedia

Compugen logo

Compugen Ltd. is a biotechnology company that focuses on the discovery and development of therapeutic and diagnostic products. The company is headquartered in Holon, Israel, and operates in the fields of immuno-oncology, oncology, and autoimmune diseases.

History[edit | edit source]

Compugen Ltd. was founded in 1993 by Dr. Eli Mintz and Dr. Simchon Faigler. The company initially focused on computational biology and bioinformatics, leveraging its proprietary predictive discovery platforms to identify novel drug targets and biomarkers.

Technology[edit | edit source]

Compugen utilizes a unique computational predictive discovery platform that integrates various biological data sources to identify novel drug targets and biomarkers. This platform is designed to accelerate the drug discovery process by predicting the potential efficacy and safety of new therapeutic candidates.

Therapeutic Areas[edit | edit source]

Compugen's primary focus areas include:

  • Immuno-oncology: Developing therapies that harness the body's immune system to fight cancer.
  • Oncology: Targeting various types of cancer with novel therapeutic approaches.
  • Autoimmune diseases: Discovering treatments for diseases where the immune system attacks the body's own tissues.

Pipeline[edit | edit source]

Compugen has a robust pipeline of therapeutic candidates in various stages of development. Some of the key candidates include:

  • COM701: An anti-PVRIG antibody for the treatment of solid tumors.
  • COM902: An anti-TIGIT antibody for the treatment of various cancers.
  • CGEN-15001T: A novel immune checkpoint inhibitor.

Collaborations and Partnerships[edit | edit source]

Compugen has established several strategic collaborations and partnerships with leading pharmaceutical companies and research institutions to advance its drug discovery and development efforts. Notable partners include Bristol-Myers Squibb and Bayer.

Leadership[edit | edit source]

The company's leadership team comprises experienced professionals from the biotechnology and pharmaceutical industries. The current CEO is Dr. Anat Cohen-Dayag, who has been with the company since 2002.

See Also[edit | edit source]

References[edit | edit source]

External Links[edit | edit source]

Contributors: Prab R. Tumpati, MD